LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study).

    Moser, Othmar / Müller, Alexander / Aberer, Felix / Aziz, Faisal / Kojzar, Harald / Sourij, Caren / Obermayer, Anna / Abbas, Farah / Birnbaumer, Philipp / Lenz, Jacqueline / Mursic, Ines / Sternad, Christoph / Hönger, Lukas / Ziko, Haris / Pferschy, Peter N / Tripolt, Norbert / Sourij, Harald

    Diabetes technology & therapeutics

    2023  Volume 25, Issue 3, Page(s) 161–168

    Abstract: Aims: ...

    Abstract Aims:
    MeSH term(s) Male ; Adult ; Humans ; Middle Aged ; Insulin Glargine ; Diabetes Mellitus, Type 1 ; Hypoglycemic Agents ; Cross-Over Studies ; Blood Glucose
    Chemical Substances Insulin Glargine (2ZM8CX04RZ) ; insulin degludec (54Q18076QB) ; Hypoglycemic Agents ; Blood Glucose
    Language English
    Publishing date 2023-01-02
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2022.0422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Conference proceedings: Der Einfluss von regelmäßigem kontrolliertem Ausdauertraining über 13 Wochen auf die physische Leistungsfähigkeit bei Menschen mit Typ 1 Diabetes – eine Analyse aus der Ultraflexi-1 Studie

    Müller, Alexander / Aberer, Felix / Abbas, Farah / Lenz, Jacqueline / Sternad, Christoph / Eckstein, Max Lennart / Hönger, Lukas / Weber, Barbara / Mursic, Ines / Zanker, Matthias / Unteregger, Christina / Kojzar, Harald / Sourij, Caren / Pferschy, Peter / Tripolt, Norbert / Moser, Othmar / Sourij, Harald

    Diabetologie und Stoffwechsel

    2022  Volume 17, Issue S 01

    Event/congress Diabetes Kongress 2022 - 56. Jahrestagung der DDG, CityCube Berlin, 2022-05-25
    Language German
    Publishing date 2022-05-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article ; Conference proceedings
    ZDB-ID 2222993-0
    ISSN 1861-9010 ; 1861-9002
    ISSN (online) 1861-9010
    ISSN 1861-9002
    DOI 10.1055/s-0042-1746243
    Database Thieme publisher's database

    More links

    Kategorien

  3. Article ; Online: Impact of COVID-19 Vaccination on Glycemia in Individuals With Type 1 and Type 2 Diabetes: Substudy of the COVAC-DM Study.

    Aberer, Felix / Moser, Othmar / Aziz, Faisal / Sourij, Caren / Ziko, Haris / Lenz, Jacqueline / Abbas, Farah / Obermayer, Anna M / Kojzar, Harald / Pferschy, Peter N / Müller, Alexander / Unteregger, Christina / Leitner, Marlies / Banfic, Tamara / Eckstein, Max L / Wachsmuth, Nadine / Kaser, Susanne / Mader, Julia K / Tripolt, Norbert J /
    Sourij, Harald

    Diabetes care

    2021  Volume 45, Issue 2, Page(s) e24–e26

    MeSH term(s) COVID-19 ; COVID-19 Vaccines ; Diabetes Mellitus, Type 2 ; Humans ; SARS-CoV-2 ; Vaccination
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-11-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 441231-x
    ISSN 1935-5548 ; 0149-5992
    ISSN (online) 1935-5548
    ISSN 0149-5992
    DOI 10.2337/dc21-1563
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study.

    Sourij, Caren / Tripolt, Norbert J / Aziz, Faisal / Aberer, Felix / Forstner, Patrick / Obermayer, Anna M / Kojzar, Harald / Kleinhappl, Barbara / Pferschy, Peter N / Mader, Julia K / Cvirn, Gerhard / Goswami, Nandu / Wachsmuth, Nadine / Eckstein, Max L / Müller, Alexander / Abbas, Farah / Lenz, Jacqueline / Steinberger, Michaela / Knoll, Lisa /
    Krause, Robert / Stradner, Martin / Schlenke, Peter / Sareban, Nazanin / Prietl, Barbara / Kaser, Susanne / Moser, Othmar / Steinmetz, Ivo / Sourij, Harald

    Diabetes, obesity & metabolism

    2022  Volume 24, Issue 5, Page(s) 849–858

    Abstract: Aims: To investigate the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without ... ...

    Abstract Aims: To investigate the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without diabetes.
    Materials and methods: This prospective, multicentre cohort study analysed people with type 1 and type 2 diabetes and a glycated haemoglobin level ≤58 mmol/mol (7.5%) or >58 mmol/mol (7.5%), respectively, and healthy controls. Roche's Elecsys anti-SARS-CoV-2 S immunoassay targeting the receptor-binding domain was used to quantify anti-spike protein antibodies 7 to 14 days after the first and 14 to 21 days after the second vaccination.
    Results: A total of 86 healthy controls were enrolled in the study, as well as 161 participants with diabetes, of whom 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% of participants in the type 1 diabetes group and 48.0% of those in the type 2 diabetes group showed antibody levels above the cut-off for positivity. Antibody levels after the second vaccination were similar in participants with type 1 diabetes, participants with type 2 diabetes and healthy controls after adjusting for age, sex and multiple testing (P > 0.05). Age (r = -0.45, P < 0.001) and glomerular filtration rate (r = 0.28, P = 0.001) were significantly associated with antibody response.
    Conclusions: Anti-SARS-CoV-2 S receptor-binding domain antibody levels after the second vaccination were comparable in healthy controls and in participants with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.
    MeSH term(s) COVID-19/prevention & control ; COVID-19 Vaccines/therapeutic use ; Cohort Studies ; Diabetes Mellitus, Type 2/complications ; Humans ; Immunity, Humoral ; Prospective Studies ; Vaccination
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2022-01-24
    Publishing country England
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.14643
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Humoral immune response to Covid-19 vaccination in diabetes: age-dependent but independent of type of diabetes and glycaemic control-the prospective COVAC-DM cohort study

    Sourij, Caren / Tripolt, Norbert Joachim / Aziz, Faisal / Aberer, Felix / Forstner, Patrick / Obermayer, Anna / Kojzar, Harald / Kleinhappl, Barbara / Pferschy, Peter Nikolaus / Mader, Julia K / Cvirn, Gerhard / Goswami, Nandu / Wachsmuth, Nadine / Eckstein, Max L / Mueller, Alexander / Abbas, Farah / Lenz, Jacqueline / Steinberger, Michaela / Knoll, Lisa /
    Krause, Roebrt / Stradner, Martin Helmut / Schlenke, Peter / Sareban, Nazanin / Prietl, Barbara / Kaser, Susanne / Moser, Othmar / Steinmetz, Ivo / Sourij, Harald

    medRxiv

    Abstract: Aims: Immune response to COVID-19 vaccination and a potential impact of glycaemia on antibody levels in people with diabetes remains unclear. We investigated the seroconversion following first and second COVID-19 vaccination in people with type 1 and ... ...

    Abstract Aims: Immune response to COVID-19 vaccination and a potential impact of glycaemia on antibody levels in people with diabetes remains unclear. We investigated the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and analysed the response in comparison to individuals without diabetes. Materials and Methods: This prospective, multicenter cohort study analysed people with type 1 and type 2 diabetes, well (HbA1c<7.5% or <58 mmol/mol) or insufficiently (HbA1c≥7.5% or ≥58 mmol/mol) controlled and healthy controls. Roche9s Elecsys anti-SARS-CoV-2 S was used to quantify anti-spike protein antibodies 7-14 days after the first and 14-21 days after the second vaccination. Results: 86 healthy controls and 161 participants with diabetes were enrolled, 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% in the type 1 diabetes group and 48.0% in the type 2 diabetes group showed antibody levels above the cut-off for positivity. Antibody levels after the second vaccination were similar in people with type1, type 2 diabetes and healthy controls if adjusted for age, sex and multiple testing (p>0.05). Age (r=-0.45, p<0.001) and glomerular filtration rate (r=0.28, p=0.001) were significantly associated with antibody response. Conclusions: Anti-SARS-CoV-2 S antibody levels after the second vaccination were comparable in healthy controls, people with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.
    Keywords covid19
    Language English
    Publishing date 2021-11-09
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.11.05.21265849
    Database COVID19

    Kategorien

To top